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Abstract
Background: Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in
survival pathways in cancer. The purpose of this study is to further explore the roles of PDCD6 in epithelial ovarian
cancer.
Methods: Lentiviral vector with shRNA for PDCD6 was used to investigate the effects of PDCD6 knockdown on
cell growth, cell cycle, apoptosis and motility in ovarian cancer cells. Two hundred twelve epithelial ovarian cancer
tissues were analyzed for mRNA expression of PDCD6 using RT-PCR. Associations of its expression with clinical
pathological factors, progression free and overall survival were evaluated.
Results: PDCD6 is highly expressed in metastatic ovarian cancer cells and positively regulates cell migration and
invasion. Significantly, the level of PDCD6 expression in epithelial ovarian cancer correlates with clinical progression.
Patients with medium or high levels of PDCD6 mRNA were at higher risk for disease progression, compared to
those with low levels (HR, 1.29; P = 0.024 for medium levels; and HR, 1.57; P = 0.045 for high levels) after adjusting
for age, disease stage, tumor grade, histologic type and residual tumor size. Kaplan-Meier survival analysis
demonstrated similar results. However, no association was found between PDCD6 expression and overall survival.
Conclusions: PDCD6 seems to play an important role in ovarian cancer progression and it may be an
independent predictor of progression free survival in epithelial ovarian cancer. Further studies are needed to more
completely elucidate the molecular mechanisms of PDCD6 involve in ovarian cancer progression.
Background
Ovarian cancer is a common gynecologic malignancy
and a major cause of cancer death among women in the
United States [1]. The 5-year survival rate for patients
with ovarian cancer is only 35% [2,3]. The high mortal-
ity of ovarian cancer is related to our inability to detect
the disease early and to treat it effectively. Most of ovar-
ian cancer patients ultimately die from tumor recur-
rence and metastasis, despite t h ef a c tt h a tt h e yi n i t i a l l y
respond to the treatment of cytoreductive surgery fol-
lowed by paclitaxel and platinum-based chemotherapy.
So, understanding the molecular mechanisms involving
the initiation, progression, and metastasis of ovarian
cancer is important for the prevention, detection, and
treatment of ovarian cancer.
In our previous study, two epithelia ovarian cancer cell
lines with low and high metastatic potentials were set
up successively, named as HO-8910, and HO-8910 PM
respectively [4,5]. Seventeen different significantly
expressed proteins between them were detected by com-
parative proteomic analysis, of which programmed cell
death 6 (PDCD6), also named as apoptosis-linked gene
2 (ALG-2), was identified [6].
PDCD6, a calcium-binding protein belonging to the
penta-EF-hand protein family, participates in T cell
receptor-, Fas-, and glucocorticoid-induced programmed
cell death [7,8]. However, apoptosis was not blocked in
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tionally redundant [9]. Furthermore, PDCD6 was found
up-regulated in lung cancer and hepatoma tissue com-
pared with normal tissue, also suggesting that PDCD6
beside its known proapoptotic functions may be a player
in survival pathways [10]. Similarly, our previous results
showed PDCD6 was over-expressed in HO-8910 PM
which has higher metastatic potential, as compared with
HO-8910 [6]. To further explore the function of PDCD6
in ovarian cancer, in this study, we investigated the
effects of PDCD6 knockdown by short hairpin RNA
(shRNA) on cell growth, cell cycle, apoptosis and moti-
lity of ovarian cancer cells. In addition, we analyzed the
association between PDCD6 expression, clinical patholo-
gical factors and outcome in ovarian cancer patients.
Materials and methods
Cell culture
HO-8910 and HO-8910 PM cells were established by
Zhejiang Cancer Hospital [4,5]. The cells were cultured
in RPMI-1640 medium containing 10% newborn bovine
serum, supplemented with 100 U/ml penicillin and 125
μg/ml streptomycin, and were incubated at 37°C with
5% CO2.
Western blot analysis
The cells were harvested with 0.02% EDTA and 0.025%
trypsin, rinsed three times in phosphate-buffered saline
(PBS), and pelleted in 1.5 ml microcentrifugetubes by
centrifugation. Whole-cell extracts were prepared with
the Nuclear Extract Kit (Active Motif, Carlsbad, Califor-
nia, USA). The protein content of the cell lysate was
determined by using the Bradford calorimetric assay
method (Bio-Rad, Richmond, California, USA). Fifty μg
of cell lysates were directly resolved by 12% SDS-PAGE
and were transferred to PVDF membranes (Millipore,
MA, USA). Proteins transferred to the membrane were
detected by GAPDH and PDCD6 (Abcam Inc, MA,
USA) primary antibodies and horseradish peroxidase-
linked secondary antibodies (anti-rabbit IgG), and the
proteins were then visualized by enhanced chemilumi-
nescence reagents. BioRad Laboratories Quantity One
software (BioRad, CA, USA) was used to quantify the
blots, GAPDH as a loading control.
Quantitative real-time polymerase chain reaction (qRT-
PCR)
RNeasy Mini Kits (QIAGEN Inc., Valencia, CA) were
used to extract total RNA from cells and tissue. RNA (5
ng) was reverse transcribed to cDNA using a Super-
Script First-Strand Synthesis System for RT-PCR (Invi-
trogen Corp., Carlsbad, CA). Quantitative real-time PCR
was performed to determine the expression level of
PDCD6 mRNA in each tumor sample, using GAPDH as
an endogenous control for calibration. The primer
sequences were designed online (http://www.idtdna.
com) and ordered from Invitrogen Corp. (Shanghai,
China). The primer sequences were: TGA CCA GTT
CCA CGA CAT CCT CAT (PDCD6 forward), TTG
GCT CTT TCC ATG TTG TGC TGC (PDCD6
reverse), GAA GGT GAA GGT CGG AGT C (GAPDH
forward), and GAA GAT GGT GAT GGG ATT TC
(GAPDH reverse). Quantitative real time PCR was car-
ried out using an ABI 7500 real-time PCR system
(Applied Biosystems Inc., Foster City, CA, USA). The
PCR reaction solution (25 μl) contained 5 ng/μlc D N A ,
12.5 μl Power SYBR Green PCR Master Mix (Bioer
Technology Inc., Hangzhou, China) and a pair of pri-
mers at a final concentration of 5 μMf o rPDCD6 and
GAPDH. Dissociation curve analysis was performed after
PCR to confirm the size of PCR products. All tumor
samples were analyzed in duplicate along with negative
controls. Real-time PCR results were recorded as Ct
values (threshold cycle). To adjust for the total amount
of cDNA used for analysis in each sample, a ΔCt was
calculated based on the difference in Ct values between
the target gene PDCD6 and the housekeeping gene
GAPDH. ΔCt was further converted to an expression
index (EI) based on the formula 2
(-ΔCt). Inhibition rate
of PDCD6 was calculated by formula [1-2
(-ΔΔCt)]*100%.
Transfection of lentiviral vectors with shRNA for PDCD6
The pGCSIL-GFP-shRNA-PDCD6 lentiviral vectors
(pGCSIL, a lentiviral vector) were purchased from
Shanghai GeneChem Company and the target shRNA
sequences as follows: 5’- cagagggtcgataaagaca-3’.
pGCSIL-GFP-lentiviral vector was used as a control.
The lentiviral vectors and pHelper were co-transfected
into 293 T cells. The culture supernatants were col-
lected, concentrated, and used as a virus stock. HO-
8910 PM at 40%-50% confluence was inflected with len-
tivirus expression shRNA to the human PDCD6 gene or
vector control. The shRNA targeting sequences was vali-
dated for the most efficient interference of PDCD6 by
qRT-PCR and Immunoblotting.
Cell proliferation assay
To assess cell proliferation effected by PDCD6, HO-
8910 PM cells was infected with shRNA-PDCD6 for 72
h. Then the cells were plated at 5 × 10
3 cells/well in 96-
well microtiter plates and cultured at 37°C with 5%
CO2. Each 24 h, the cell viability was measured by MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide) reagent (Sigma, St Louis, MO, USA) according
to the manufacturer’s instructions. Briefly, add reconsti-
tuted MTT in an amount equal to 10% of the culture
medium volume. Return to incubator for 2 h. After that,
medium was moved, and MTT formazan was resolved
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at a wavelength of 570 nm. Experiments were performed
in triplicate, and 3 different experiments were performed
for each experimental condition. A cell proliferation
curve was constructed by measuring cell growth for 4
consecutive days.
Cell cycle assay
Cell cycle distribution was monitored by flow cytometry
(FACSCalibur, Becton Dickinson, Franklin Lakes, NJ,
USA) using propidium iodine (PI) staining (Becton
Dickinson) according to the protocol of the manufac-
turer. Briefly, the H0-8910 PM cells which were pre-
infected with shRNA-PDCD6 for 72 h were plated in 6-
well plates. After cultured for 48 h, cells were collected,
washed with PBS, and fixed with 2% paraformaldehyde
at room temperature for 30 min. After paraformalde-
hyde was moved, cell pellets were resuspended by 70%
ethanol and stored at -20°C for 2 h. Then spin cells out
of fix, pellets were resuspend in PBS with 200 ug/ml
RnaseA and incubated at 37°C for 1 h. Added PI to a
final concentration of 50 ug/ml for 2 h before analyzing
on the flow cytometer.
Software-based cell cycle analysis was performed using
ModFit 2.0 (Verity, Topsham, ME).
Hoechst stain for detecting apoptotic cells
Apoptotic cells were detected by fluorescence imaging
using Hoechst 33258 stain (Sigma-Aldrich, St. Louis,
MO, USA). Seventy-two hours after transfection, cells
were washed twice with PBS, and then incubated with
Hoechst reagent (10 mg/ml) for 30-45 min at 37°C in
the dark. Morphological changes including a reduction
in volume and nuclear chromatin condensation were
observed under a fluorescence microscope (Nikon,
Tokyo, Japan) and photographed at a magnification of
200×. Apoptotic cells were counted in at least three to
four random fields and expressed as percentage of total
cells.
Transwell migration and invasion assay
For transwell migration assays, cells were plated in the
top chamber with the non-coated membrane (24-well
insert; pore size, 8 mm; BD Biosciences). For invasion
assays, cells were plated in the top chamber with Matri-
gel-coated membrane (24-well insert; pore size, 8 mm;
BD Biosciences). In both assays, a number of 2 × 10
5
HO-8910 PM cells treatment in 100 μLs e r u m - f r e e
medium were pre-infected with shRNA-PDCD6 for 72 h
and added to the upper chamber, while 500 μL medium
with 10% FBS were added to the lower chamber. Trans-
wells were incubated for 24 h at 37°C. Cells on the
inside of the transwell inserts were removed with a cot-
ton swab, and cells on the underside of the insert filter
were fixed and stained. Photographs of four random
fields were taken, and the cells were counted to calcu-
late the average number of cells that had transmigrated.
Patients and follow-up
Patient samples of ovarian cancer were consecutively
collected in the Gynecologic Oncology Unit at Univer-
sity of Turin in Italy between October 1991 and Febru-
ary 2000 and all participants gave informed consent.
Use of tissue samples was approved with an Ethical
Review Committee of University. All ovarian cancer tis-
sues were obtained at the time of cytoreductive surgery.
In this study, we identified 212 patients with primary
epithelial ovarian cancer who underwent cytoreductive
surgery. The average patient age at surgery was 57.6
years (SD, 11.5; range, 26-82). Follow-up information
was available for 203 patients who were followed from
surgery to June 2001. The overall follow-up time ranged
from 0.6 to 114 months, and the median was 31
months. The median disease progression-free survival
was 20.6 months. Disease staging was classified accord-
ing to the criteria of FIGO (the International Federation
of Gynecologists and Obstetricians)[11]. Of the 211
patients with information on disease stage, 51 (24.2%)
were diagnosed with stage I disease, 12 (5.7%) were
stage II, 133 (63.0%) were stage III, and 15 (7.1%) were
stage IV. Histological type determined following the
World Health Organization (WHO) criteria [12]
included serous, endometrioid, mucinous, clear cell, and
other epithelial tumors. For data analysis, tumor histo-
types were grouped into non-serous (59.9%, n = 127)
and serous (40.1%, n = 85). Of the 211 patients with
information on tumor grade, most patients (65.4%, n =
138) had grade 3 tumors (poorly differentiated); few had
grade 1 or 2 (34.6%, n = 73). After surgery, most of the
patients were treated with platinum-based chemotherapy
following a standard protocol.
Statistical analysis
The data from in vitro experiments were expressed as
the mean ± SD for 3 independent experiments using
three difference preparations. The difference between
the means was assessed by Student’s t-test. For patient
study, PDCD6 mRNA expression was analyzed as a con-
tinuous variable and as a categorical variable after
grouping by expression index (EI) distribution as low
expression (EI < 0.1), middle expression (EI 0.1-1) and
high expression (EI > 1). Associations between PCDC6
expression and clinical variables were analyzed using the
Chi-square test. Survival analysis was performed for pro-
gression-free and overall survival using the Cox propor-
tional hazards regression and Kaplan-Meier curves. All
p-values were two-sided, and a probability of 0.05 or
smaller was considered statistical significance. SPSS
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analysis.
Results
Expression of PDCD6 in ovarian cancer cell lines with
different metastatic potential
To confirm our previous proteomic results [6], we com-
pared the expression of PDCD6 in H0-8910 and H0-
8910 PM cells by western blot. The results showed that
PDCD6 expression was higher in H0-8910 PM than that
in H0-8910 (Figure 1A).
Knockdown of PDCD6 in HO-8910 PM cells by lentiviral
vectors-mediated transfection
In the present study, lentiviral vectors-mediated trans-
fection was used to determine effects of PDCD6 expres-
sion silencing on metastatic ovarian cancer cell
behavior. Seventy two hours after transfection, HO-8910
PM cells were observed using a fluorescent microscope.
T h et r a n s f e c t i o ne f f i c i e n c yw a se v a l u a t e db yc o u n t i n g
the green fluorescent cells, which was over 95% when
the cells were infected with a multiplicity of infection
(MOI) of 3. mRNA and protein levels of PDCD6 were
detected by RT-PCR and Western blot at 72 h after
transfection. The results showed pGCSIL-GFP-shRNA-
PDCD6 lentiviral vector was effective in silencing
PDCD6 expression and the inhibition rate of PDCD6
was about 80% (Figure 1B-C).
Influence of HO-8910 PM cell proliferation, apoptosis and
cell cycle by PDCD6 expression silencing in vitro
A ss h o w ni nF i g u r e2 ,P D C D 6k n o c k d o w nh a dn o
obvious effect on cell proliferation and apoptosis
although apoptotic cells were increased slightly and cell
growth slowed down a little bit in HO-8910 PM cells
infected with shRNA-PDCD6. No significant difference
of cell cycle distribution was found.
Inhibition of HO-8910 PM migration and invasion in vitro
by siRNA-mediated PDCD6 knockdown
Migration and invasion assay in vitro were carried out
to evaluate PDCD6 knockdown on HO-8910 PM cell
motility. The result showed that the average number of
migrated and invaded HO-8910 PM cells transfected
with siRNA significantly decreased in comparison with
the Mock group, p < 0.001 and P = 0.050 respectively
(Figure 3).
Correlation of PDCD6 mRNA expression with disease
characteristics and patient survival
Spearman correlation analysis showed PDCD6 expres-
sion was positively correlate with residual tumor size (r
=0 . 1 6 ,p = 0.019) (Table 1). Compared the median
expressions of PDCD6 by different clinical and patholo-
gic characteristics, no significant difference was found,
although PDCD6 expression was slight higher in
advanced (stagesIII and IV) than that in early disease
Figure 1 A. Western blotting analysis showed protein
expression of PDCD6 was higher in HO-8910 PM cells than
that in HO-8910 cells. GAPDH was used as a loading control. B.
Western blotting analysis showed protein expression of PDCD6 in
shRNA-PDCD6-HO-8910 PM was decreased compared with that in
control HO-8910 PM-mock. GAPDH was used as a loading control.
C. qRT-PCR results showed mRNA expression of PDCD6 in shRNA-
PDCD6-HO-8910 PM was inhibited by 80% compared with that in
HO-8910 PM-mock.
Figure 2 A. Growth curve of HO-8910 PM cells infected with
control or siRNA-PDCD6. At each indicated time point, cell
viability was determined and represented as the degree of
absorbance 570 nm using the MTT. The mean ± SD absorbance
(triplicate wells) for each time point is plotted as a function of the
number of days after seeding. B. Cell cycle distribution in shRNA-
PDCD6-HO-8910 PM and HO-8910 PM-mock cells. C. Apoptosis
analysis in shRNA-PDCD6-HO-8910 PM and HO-8910 PM-mock cells
by Hoechst 33258 staining. Normal cells showed normal nuclei blue,
while apoptotic cells showed the cell nucleus was chunky, stainded
densely and brightly.
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poorly differentiated tumors (grade3) than in well-differ-
entiated tumors (grade 1 or 2), 0.29 versus 0.16, p =
0.275. Patients who had residual tumor after surgery
had higher PDCD6 expression than patients who had no
residual tumor, 0.31 versus 0.18, p = 0.261 (Table 2).
Similar results were found when categorical variable was
analyzed (Table 2), but significant difference of PDCD6
expression was showed between the patients with resi-
dual tumor and without residual tumor after surgery.
Patients with residual tumor had significantly higher
PDCD6 expression than patients who had no residual
tumor (29.3% versus 16.7%, P = 0.050).
PDCD6 mRNA expression was significantly associated
with progression free survival (Table 3). Patients with
medium or high levels of PDCD6 mRNA were at higher
risk for disease progression, compared to those with low
levels (HR, 1.29; P = 0.024 for mid levels; and HR, 1.57;
P = 0.045 for high levels) after adjusting for age, disease
stage, tumor grade, histologic type and residual tumor
size. Kaplan-Meier survival analysis demonstrates similar
results. Patients who had medium or high PDCD6
mRNA had worse progression free survival (Figure 4).
No significant association was found between PDCD6
mRNA expression and overall survival although patients
with medium or high levels of PDCD6 mRNA were at
higher risk for death compared to those with low level.
Discussion
In our proteomic analysis of ovarian cancer cell lines,
we detected 21 significantly different spots (two-fold
increase or decrease) through 2-D gel electrophoresis, of
which 17 candidate proteins were successfully identified
and characterized. These proteins were mainly involved
in the regulation of cell growth, proliferation, motility,
apoptosis and tumor immunity [6]. To further study the
function of those differentially expression proteins in
ovarian cancer, in this study, we selected PDCD6, which
had the highest protein score and 100% protein confi-
dence interval [6]. As expected, PDCD6 overexpression
in HO-8910 PM as compared to HO-8910 was con-
firmed by western blot analysis.
PDCD6, discovered by cDNA library screening for
apoptosis-related genes [13], is a calcium binding pro-
tein which belongs to the penta-EF-Hand family that
has the Ca2 + -binding helix-loop-helix structures [14].
PDCD6 functions as a Ca2+ sensor by changing its con-
formation [15]. This conformational change enables
PDCD6 to interact with various intracellular proteins
containing Pro-rich regions in a Ca2 + -dependent
manner, such as Alix (ALG-2-interacting protein X)[16],
annexins VII, XI [17], Sec31A (SEC31 homolog A)[18],
and TSG101 (tumor susceptibility gene 101)[16]. Origi-
nal cloning report of PDCD6 cDNA in a screen for
genes involved in apoptosis [13] and early studies indi-
cated PDCD6 participates in T cell receptor-induced
programmed cell death in a Ca2 + -dependent manner
as a pro-apoptotic factor [19]. Recent study showed
Alix and ALG-2 involved in tumor necrosis factor
receptor 1-induced cell death by interacting with pro-
caspase-8 [20]. However, apoptosis was not blocked in
PDCD6 deficient mice, suggesting that PDCD6 is func-
tionally redundant [21]. Furthermore, PDCD6 was
found to be up-regulated in a variety of human tumors
compared to normal tissues of the breast, liver, lung,
and colon, especially in metastatic tissues, which sug-
g e s t st h a ti na d d i t i o nt oi t sk n o w np r o - a p o p t o t i cf u n c -
tion PDCD6 may play a role in cell survival [22-24].
Additionally, in vitro experiments indicated that PDCD6
had an anti-apoptotic action in HeLa cells via facilitat-
ing proliferating cells passing through the G2/M cell
cycle checkpoints [25].
Figure 3 A. Migrated cells in shRNA-PDCD6-HO-8910 PM and
HO-8910 PM-mock cells. Magnification in × 100. B. Quantitative
analysis for migration and invasion assays of HO-8910 PM infected
with shRNA-PDCD6 or control.
Table 1 Spearman correlation of PDCD6 mRNA
expressions with clinicopathologic features of ovarian
cancer
Variable PDCD6 mRNA expression
correlation coefficient (P)
Age (n = 209) -0.03 (0.642)
Disease stage (n = 211) 0.07 (0.310)
Tumor grade (n = 211) 0.02 (0.748)
Tumor histology (n = 212) 0.00 (0.954)
Residual tumor size (n = 206) 0.16 (0.019)
a
a Bold values are statistically significant (p < 0.05)
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had no obvious effect on cell proliferation and apoptosis
although apoptotic cells were increased slightly and cell
growth slowed down a little bit in HO-8910 PM cells
infected with shRNA-PDCD6, but did result in decrease
in cell motility and invasiveness. These results indicated
that over expression of PDCD6 promote both migration
and invasion in ovarian cancer cells.
Significantly, our patient study supported the results
in vitro. PDCD6 mRNA expression was significantly
correlated with residual tumor size. Patients with resi-
dual tumor had higher PDCD6 expression than patients
with no residual tumor. Furthermore, PDCD6 expres-
sion was associated with patient survival; patients with
high PDCD6 mRNA had shorter disease progression-
free survival than those with middle or low expression.
Our findings suggest that PDCD6 mRNA expression is
an independent predictor of ovarian cancer progression
free survival.
In the study, we found that high PDCD6 expression
was associated with disease progression, but not death.
There are a number of possible reasons that may
explain this discrepancy. First, PDCD6 may promote
disease progression or reduce the effect of adjuvant
treatment by stimulating tumor cell migration or inva-
sion, but these effects do not lead to the death of all
cases. Some patients may die of other reasons. Second,
the study was relatively small and the follow-up time
Table 2 Association of PDCD6 mRNA expression with clinical and pathological characteristics of ovarian cancer
PDCD6 Expression
Variable n Median (5th-95th)
a p-value
b Low
c Middle
d High
e p-value
f
Stage 211 n (%) n (%) n (%)
I-II 63 0.16 (0-4.78) 0.183 25(39.7) 28(44.4) 10(15.9) 0.256
III-IV 148 0.28 (0-5.26) 52(35.1) 57(38.5) 85(26.4)
Grade 211
1~2 73 0.16 (0-4.41) 0.275 26(35.6) 33(45.2) 14(19.2) 0.477
3 138 0.29 (0-5.53) 51(37.0) 52(37.7) 35(25.4)
Histology 212
Non-Serous 127 0.20 (0-5.03) 0.321 47(37.0) 53(41.7) 27(21.3) 0.734
Serous 85 0.28 (0-5.41) 30(35.3) 33(38.8) 22(25.9)
Residual Tumor 206
No Residual 90 0.18 (0-3.69) 0.261 32(35.6) 43(47.8) 15(16.7) 0.050
h
Residual 116 0.31 (0-7.20) 43(37.1) 39(33.6) 34(29.3)
a Expression levels at the 5th and 95th percentiles;
b Wilcoxon two-sample test with t approximation;
c Low: Expression Index (EI) < 0.1;
d Middle: Expression Index (EI) 0.1-1;
e High: Expression Index (EI) > 1;
f p-value from Chi-square test;
g p-value from Spearman correlation test;
h Bold values are statistically significant (p < 0.05)
Table 3 Associations of PDCD6 mRNA expression and
patient survival
a
Crude
HR
95%
CI
b
p-
value
Adjust
HR
95% CI p-
value
Disease-Free Survival
c
Low
PDCD6
11
Mid PDCD6 1.65 1.01-
2.70
0.046 1.29 1.08-
2.91
0.024
High
PDCD6
1.87 1.09-
3.21
0.023 1.57 1.09-
2.58
0.045
Overall Survival
d
Low
PDCD6
11
Mid PDCD6 1.51 0.93-
2.43
0.094 1.88 0.95-
3.08
0.092
High
PDCD6
1.13 0.64-
1.99
0.664 1.07 0.61-
1.91
0.801
a Associations determined by Cox proportional hazards regression and
adjusted for age, stage, grade, histotype and residual tumor size. Significance
level of p = 0.05
b 95% Wald Confidence Limits
c Hazard Ratio (HR) for relapse with respect to low PDCD6 expression
d Hazard Ratio (HR) for death with respect to low PDCD6 expression
Figure 4 Kaplan-Meier progression-free survival curves (A) and
overall survival curves (B) according to PDCD6 levels: Among
the patients, 77 patients had low PDCD6 expression, 86
patients had medium PDCD6 expression, and 49 patients had
high PDCD6 expression.
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nificant association with overall survival. Third, our
study findings are still preliminary. Independent large
studies are needed to confirm these results.
These findings may be explained by our observations in
vitro and vivo which are generally in agreement with the
findings of other studies. One study of lung cancer
demonstrated that PDCD6 overexpression was indicative
of unfavorable prognosis for patients with early stage
non-small cell lung cancer or lung adenocarcinoma; the
protein may serve as a potential molecular marker for
aggressive lung cancer [23]. However, no association was
found between PDCD6 protein expression measured by
immunohistochemical staining and survival of lung,
breast or colon cancer patients [26]. And recent study
reported that purified recombinant human PDCD6 inhi-
bits vascular endothelial growth factor (VEGF)-induced
proliferation, invasion, and capillary-like structure tube
formation in vitro through PI3K/mTOR/p70S6K pathway
by interacting of VEGFR-2 [27]. Those inconsistent find-
ings in the literature may be due to the observations
made on different cancer cell lines or disease stages. In
early stage tumors or tumors other than ovarian cancer,
P D C D 6m a yh a v eap r o - a p o p t o t i ce f f e c to nt h et u m o r s ,
whereas in our case when the tumor is ovarian cancer or
tumors progress to advanced stages (since most of ovar-
ian cancers are grade 3 tumors), the PDCD6 function
changes to an opposite direction either due to different
regulation or downstream targets, which is anti-apoptotic
or pro-migration that leads to shortened progression-free
survival.
In the future, we will continue this work from clinic to
confirm its prognostic utility as well as from lab experi-
ment to elucidate its molecular mechanism, finding or
assembling another clinical study to measure PDCD6
expression in ovarian tumors and to analyze its associa-
tion with disease progression and overall survival, per-
forming chip assay to identify upstream modulators of
PDCD6 as well as its downstream targets or pathways
being involved in the PDCD6’s effect on tumor progres-
sion. With a comprehensive understanding of PDCD6
regulation and function, we may be able to tell what
confounding biology is involved in the relationship
between PDCD6 expression and ovarian cancer
progression.
Conclusions
In summary, PDCD6 was identified and characterized as
differentially expressed proteins between ovarian cancer
cells with low and high metastatic property by our pre-
vious comparative proteomic study. It was further con-
firmed to be overexpressed in HO-8910 PM as
compared to HO-8910 by western blot. PDCD6 knock-
down significantly inhibited migration and invasion of
ovarian cancer cells in vitro, supporting the notion that
PDCD6 played an important role in ovarian cancer pro-
gression. PDCD6 mRNA was detectable in most of ovar-
ian tumor samples, and the expression was correlated
with residual tumor size. High PDCD6 expression was
found to be associated with unfavorable prognosis of the
disease. It may serve as an independent marker for ovar-
ian cancer prognosis. Further studies are needed to
more completely elucidate the molecular mechanisms of
PDCD6 in ovarian cancer progression.
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